-
It's Easy To Be Skeptical Of Mylan, But Don't Ignore This Pending PDUFA Date
Monday, May 22, 2017 - 12:25pm | 600Read More...Commenting on Mylan N.V. (NASDAQ: MYL), Barclays said there's understandably reason to be skeptical that the company will win approval for its generic version of Copaxone now after years of promises. That said, the firm thinks Mylan's chances are better than current market expectations. Analysts...
-
Sanofi May Now Have Moved Past Its Most Challenging Period, Analyst Initiates At Buy
Thursday, April 6, 2017 - 1:08pm | 365Read More...Argus' Stephen Biggar initiated coverage of Sanofi SA (ADR) (NYSE: SNY) with a Buy rating and $50 price target as the company has moved past a challenging period. According to Biggar, Sanofi has suffered through a period in which two of its best selling drugs, Lantus (diabetes) and Plavix (...
-
Orphan Drugs Among 2015's Top 10 Best-Selling Medications
Wednesday, January 18, 2017 - 11:40am | 453Read More...Orphan drugs, drugs intended to prevent, diagnose or treat rare diseases/disorders, are huge sellers for the pharmaceutical industry. NPR, citing data from EvaluatePharma, noted that seven of the 10 best-selling drugs in the United States throughout 2015 were given an orphan drug status. The main...
-
Eli Lilly Announces Guidance, U.S. Insulin Release
Thursday, December 15, 2016 - 9:55am | 488Read More...Shares of Eli Lilly and Co (NYSE: LLY) gained more than 3 percent ahead of Thursday's market open after the company provided the investment community with its financial guidance and an update to a new insulin product. Financial Guidance Eli Lilly guided its full year fiscal 2016 earnings...
-
The 5 Top-Selling Drugs In The World
Tuesday, September 20, 2016 - 12:09pm | 488Read More...The 2016 election season has brought the topic of prescription drug pricing and profits into the limelight. Most patients paying for medication are acutely aware of the billions of dollars of global drug sales that the top pharmaceutical companies rake in each year. With the elections now less than...
-
Sanofi's Stock Dips Lower Following Q4 Print
Tuesday, February 9, 2016 - 9:11am | 277Read More...Shares of Sanofi SA (ADR) (NYSE: SNY) were trading lower by more than 2 percent early Tuesday morning after the company reported its fourth quarter results. Sanofi said that it earned €1.31 per share in the fourth quarter on revenue of €9.28 billion. Wall Street analysts were expecting the company...
